Two generations of insulinotropic imidazoline compounds

Suad Efendic, Alexander M. Efanov, Per Olof Berggren, Sergei V. Zaitsev

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

The imidazoline RX871024 increased basal- and glucose-stimulated insulin release in vitro and in vivo. The compound inhibited activity of ATP-sensitive K+ channels as well as voltage-gated K+ channels, which led to membrane depolarization, an increase in the cytosolic Ca2+ concentration ([Ca2+]i), and insulin release. Importantly, RX871024 also enhanced the insulinotropic effect of glucose in cells with clamped [Ca2+]i but in the presence of high ATP and Ca2+concentration inside the cell. We believe that the latter effect on insulin exocytosis was at least in part mediated by a rise in diacylglycerol, which then activated protein kinase C (PKC) and increased the generation of arachidonic acid (AA) metabolites. Activation of both the PKC and AA pathways resulted in potentiation of glucose effects on insulin secretion. Unlike RX871024, the novel imidazoline BL11282 did not block ATP-dependent K+ channels, but similarly to RX871024, it stimulated insulin secretion in depolarized or permeabilized islets. Accordingly, BL11282 did not influence glucose and insulin levels under basal conditions either in vitro or in vivo, but it markedly enhanced the insulinotropic effects of glucose. BL11282 restored the impaired insulin response to glucose in islets from spontaneously diabetic GK rats. We conclude that BL11282 belongs to a new class of insulinotropic compounds that demonstrate a strong glucose-dependent effect on insulin exocytosis.

Original languageEnglish
JournalDiabetes
Volume51
Issue numberSUPPL. 3
StatePublished - Dec 1 2002
Externally publishedYes

Fingerprint

Imidazolines
BL 11282
Insulin
Glucose
Adenosine Triphosphate
Exocytosis
Arachidonic Acid
Protein Kinase C
Voltage-Gated Potassium Channels
Diglycerides
Membranes
2-(2-imidazolin-2-yl)-1-phenyl-1H-indole

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

Efendic, S., Efanov, A. M., Berggren, P. O., & Zaitsev, S. V. (2002). Two generations of insulinotropic imidazoline compounds. Diabetes, 51(SUPPL. 3).

Two generations of insulinotropic imidazoline compounds. / Efendic, Suad; Efanov, Alexander M.; Berggren, Per Olof; Zaitsev, Sergei V.

In: Diabetes, Vol. 51, No. SUPPL. 3, 01.12.2002.

Research output: Contribution to journalArticle

Efendic, S, Efanov, AM, Berggren, PO & Zaitsev, SV 2002, 'Two generations of insulinotropic imidazoline compounds', Diabetes, vol. 51, no. SUPPL. 3.
Efendic S, Efanov AM, Berggren PO, Zaitsev SV. Two generations of insulinotropic imidazoline compounds. Diabetes. 2002 Dec 1;51(SUPPL. 3).
Efendic, Suad ; Efanov, Alexander M. ; Berggren, Per Olof ; Zaitsev, Sergei V. / Two generations of insulinotropic imidazoline compounds. In: Diabetes. 2002 ; Vol. 51, No. SUPPL. 3.
@article{8adb5eea8e46480cb0cb377de711d425,
title = "Two generations of insulinotropic imidazoline compounds",
abstract = "The imidazoline RX871024 increased basal- and glucose-stimulated insulin release in vitro and in vivo. The compound inhibited activity of ATP-sensitive K+ channels as well as voltage-gated K+ channels, which led to membrane depolarization, an increase in the cytosolic Ca2+ concentration ([Ca2+]i), and insulin release. Importantly, RX871024 also enhanced the insulinotropic effect of glucose in cells with clamped [Ca2+]i but in the presence of high ATP and Ca2+concentration inside the cell. We believe that the latter effect on insulin exocytosis was at least in part mediated by a rise in diacylglycerol, which then activated protein kinase C (PKC) and increased the generation of arachidonic acid (AA) metabolites. Activation of both the PKC and AA pathways resulted in potentiation of glucose effects on insulin secretion. Unlike RX871024, the novel imidazoline BL11282 did not block ATP-dependent K+ channels, but similarly to RX871024, it stimulated insulin secretion in depolarized or permeabilized islets. Accordingly, BL11282 did not influence glucose and insulin levels under basal conditions either in vitro or in vivo, but it markedly enhanced the insulinotropic effects of glucose. BL11282 restored the impaired insulin response to glucose in islets from spontaneously diabetic GK rats. We conclude that BL11282 belongs to a new class of insulinotropic compounds that demonstrate a strong glucose-dependent effect on insulin exocytosis.",
author = "Suad Efendic and Efanov, {Alexander M.} and Berggren, {Per Olof} and Zaitsev, {Sergei V.}",
year = "2002",
month = "12",
day = "1",
language = "English",
volume = "51",
journal = "Diabetes",
issn = "0012-1797",
publisher = "American Diabetes Association Inc.",
number = "SUPPL. 3",

}

TY - JOUR

T1 - Two generations of insulinotropic imidazoline compounds

AU - Efendic, Suad

AU - Efanov, Alexander M.

AU - Berggren, Per Olof

AU - Zaitsev, Sergei V.

PY - 2002/12/1

Y1 - 2002/12/1

N2 - The imidazoline RX871024 increased basal- and glucose-stimulated insulin release in vitro and in vivo. The compound inhibited activity of ATP-sensitive K+ channels as well as voltage-gated K+ channels, which led to membrane depolarization, an increase in the cytosolic Ca2+ concentration ([Ca2+]i), and insulin release. Importantly, RX871024 also enhanced the insulinotropic effect of glucose in cells with clamped [Ca2+]i but in the presence of high ATP and Ca2+concentration inside the cell. We believe that the latter effect on insulin exocytosis was at least in part mediated by a rise in diacylglycerol, which then activated protein kinase C (PKC) and increased the generation of arachidonic acid (AA) metabolites. Activation of both the PKC and AA pathways resulted in potentiation of glucose effects on insulin secretion. Unlike RX871024, the novel imidazoline BL11282 did not block ATP-dependent K+ channels, but similarly to RX871024, it stimulated insulin secretion in depolarized or permeabilized islets. Accordingly, BL11282 did not influence glucose and insulin levels under basal conditions either in vitro or in vivo, but it markedly enhanced the insulinotropic effects of glucose. BL11282 restored the impaired insulin response to glucose in islets from spontaneously diabetic GK rats. We conclude that BL11282 belongs to a new class of insulinotropic compounds that demonstrate a strong glucose-dependent effect on insulin exocytosis.

AB - The imidazoline RX871024 increased basal- and glucose-stimulated insulin release in vitro and in vivo. The compound inhibited activity of ATP-sensitive K+ channels as well as voltage-gated K+ channels, which led to membrane depolarization, an increase in the cytosolic Ca2+ concentration ([Ca2+]i), and insulin release. Importantly, RX871024 also enhanced the insulinotropic effect of glucose in cells with clamped [Ca2+]i but in the presence of high ATP and Ca2+concentration inside the cell. We believe that the latter effect on insulin exocytosis was at least in part mediated by a rise in diacylglycerol, which then activated protein kinase C (PKC) and increased the generation of arachidonic acid (AA) metabolites. Activation of both the PKC and AA pathways resulted in potentiation of glucose effects on insulin secretion. Unlike RX871024, the novel imidazoline BL11282 did not block ATP-dependent K+ channels, but similarly to RX871024, it stimulated insulin secretion in depolarized or permeabilized islets. Accordingly, BL11282 did not influence glucose and insulin levels under basal conditions either in vitro or in vivo, but it markedly enhanced the insulinotropic effects of glucose. BL11282 restored the impaired insulin response to glucose in islets from spontaneously diabetic GK rats. We conclude that BL11282 belongs to a new class of insulinotropic compounds that demonstrate a strong glucose-dependent effect on insulin exocytosis.

UR - http://www.scopus.com/inward/record.url?scp=0036894391&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036894391&partnerID=8YFLogxK

M3 - Article

C2 - 12475789

AN - SCOPUS:0036894391

VL - 51

JO - Diabetes

JF - Diabetes

SN - 0012-1797

IS - SUPPL. 3

ER -